Clinical Trial Designs for the Early Clinical Development of Therapeutic Cancer Vaccines
There are major differences between therapeutic tumor vaccines and chemotherapeutic agents that have important implications for the design of early clinical trials. Many vaccines are inherently safe and do not require phase I dose finding trials. Patients with advanced cancers and compromised immune...
Saved in:
Published in | Journal of clinical oncology Vol. 19; no. 6; pp. 1848 - 1854 |
---|---|
Main Authors | , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Baltimore, MD
American Society of Clinical Oncology
15.03.2001
Lippincott Williams & Wilkins |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | There are major differences between therapeutic tumor vaccines and chemotherapeutic agents that have important implications for the design of early clinical trials. Many vaccines are inherently safe and do not require phase I dose finding trials. Patients with advanced cancers and compromised immune systems are not good candidates for assessing either the toxicity or efficacy of therapeutic cancer vaccines. The rapid pace of development of new vaccine candidates and the variety of possible adjuvants and modifications in method of administration makes it important to use efficient designs for clinical screening and evaluation of vaccine regimens. We review the potential advantages of a wide range of clinical trial designs for the development of tumor vaccines. We address the role of immunological endpoints in early clinical trials of tumor vaccines, investigate the design implications of attempting to use disease stabilization as an end point and discuss the difficulties of reliably utilizing historical control data. Several conclusions for expediting the clinical development of effective cancer vaccines are proposed. |
---|---|
AbstractList | There are major differences between therapeutic tumor vaccines and chemotherapeutic agents that have important implications for the design of early clinical trials. Many vaccines are inherently safe and do not require phase I dose finding trials. Patients with advanced cancers and compromised immune systems are not good candidates for assessing either the toxicity or efficacy of therapeutic cancer vaccines. The rapid pace of development of new vaccine candidates and the variety of possible adjuvants and modifications in method of administration makes it important to use efficient designs for clinical screening and evaluation of vaccine regimens. We review the potential advantages of a wide range of clinical trial designs for the development of tumor vaccines. We address the role of immunological endpoints in early clinical trials of tumor vaccines, investigate the design implications of attempting to use disease stabilization as an end point and discuss the difficulties of reliably utilizing historical control data. Several conclusions for expediting the clinical development of effective cancer vaccines are proposed. |
Author | Larry W. Kwak Suzanne L. Topalian Richard M. Simon Jeffrey Schlom Samir Khleif Michael Hamilton Allan Hildesheim Jay A. Berzofsky Crystal L. Mackall Seth M. Steinberg |
Author_xml | – sequence: 1 givenname: Richard M surname: SIMON fullname: SIMON, Richard M organization: Branches of Biometric Research, Environmental Epidemiology, Medicine, Pediatric Oncology, Surgery, and Metabolism; Biostatistics and Data Management Section; and Laboratory of Tumor Immunology and Biology, National Cancer Institute, Bethesda, MD, United States – sequence: 2 givenname: Seth M surname: STEINBERG fullname: STEINBERG, Seth M organization: Branches of Biometric Research, Environmental Epidemiology, Medicine, Pediatric Oncology, Surgery, and Metabolism; Biostatistics and Data Management Section; and Laboratory of Tumor Immunology and Biology, National Cancer Institute, Bethesda, MD, United States – sequence: 3 givenname: Michael surname: HAMILTON fullname: HAMILTON, Michael organization: Branches of Biometric Research, Environmental Epidemiology, Medicine, Pediatric Oncology, Surgery, and Metabolism; Biostatistics and Data Management Section; and Laboratory of Tumor Immunology and Biology, National Cancer Institute, Bethesda, MD, United States – sequence: 4 givenname: Allan surname: HILDESHEIM fullname: HILDESHEIM, Allan organization: Branches of Biometric Research, Environmental Epidemiology, Medicine, Pediatric Oncology, Surgery, and Metabolism; Biostatistics and Data Management Section; and Laboratory of Tumor Immunology and Biology, National Cancer Institute, Bethesda, MD, United States – sequence: 5 givenname: Samir surname: KHLEIF fullname: KHLEIF, Samir organization: Branches of Biometric Research, Environmental Epidemiology, Medicine, Pediatric Oncology, Surgery, and Metabolism; Biostatistics and Data Management Section; and Laboratory of Tumor Immunology and Biology, National Cancer Institute, Bethesda, MD, United States – sequence: 6 givenname: Larry W surname: KWAK fullname: KWAK, Larry W organization: Branches of Biometric Research, Environmental Epidemiology, Medicine, Pediatric Oncology, Surgery, and Metabolism; Biostatistics and Data Management Section; and Laboratory of Tumor Immunology and Biology, National Cancer Institute, Bethesda, MD, United States – sequence: 7 givenname: Crystal L surname: MACKALL fullname: MACKALL, Crystal L organization: Branches of Biometric Research, Environmental Epidemiology, Medicine, Pediatric Oncology, Surgery, and Metabolism; Biostatistics and Data Management Section; and Laboratory of Tumor Immunology and Biology, National Cancer Institute, Bethesda, MD, United States – sequence: 8 givenname: Jeffrey surname: SCHLOM fullname: SCHLOM, Jeffrey organization: Branches of Biometric Research, Environmental Epidemiology, Medicine, Pediatric Oncology, Surgery, and Metabolism; Biostatistics and Data Management Section; and Laboratory of Tumor Immunology and Biology, National Cancer Institute, Bethesda, MD, United States – sequence: 9 givenname: Suzanne L surname: TOPALIAN fullname: TOPALIAN, Suzanne L organization: Branches of Biometric Research, Environmental Epidemiology, Medicine, Pediatric Oncology, Surgery, and Metabolism; Biostatistics and Data Management Section; and Laboratory of Tumor Immunology and Biology, National Cancer Institute, Bethesda, MD, United States – sequence: 10 givenname: Jay A surname: BERZOFSKY fullname: BERZOFSKY, Jay A organization: Branches of Biometric Research, Environmental Epidemiology, Medicine, Pediatric Oncology, Surgery, and Metabolism; Biostatistics and Data Management Section; and Laboratory of Tumor Immunology and Biology, National Cancer Institute, Bethesda, MD, United States |
BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=938024$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/11251017$$D View this record in MEDLINE/PubMed |
BookMark | eNpFkUtPwzAQhC1URMvjD3BAlpC4JfiZOEeU8hQSl4K4WY6zIa7SpLILqP8eR63KZffyzY5m9hRN-qEHhC4pSSkj5HZphzRumtIizVKqhDpCMypZnuS5lBM0IzlnCVX8c4pOQ1hGVCguT9CUUiYpofkMfZad6501HV54F-ccgvvqA24Gjzct4Hvjuy0-QHP4gW5Yr6Df4KHBixa8WcP3xllcmt6Cxx_GWtdDOEfHjekCXOz3GXp_uF-UT8nr2-NzefeaWMHEJhGc2Dw3WVE0zIKtay5lbRmtasiUshVIRYq6kgUrci4yaxhnUpBGCZ7VBgQ_Q2x31_ohBA-NXnu3Mn6rKdFjTfqlfNNjTZoWOtNjTVF0tROtv6sV1P-SfS8RuN4DJsTcjY_hXDhwBVeEjd43O6p1X-2v86DDynRdPMp0fM6_3x97L37k |
CitedBy_id | crossref_primary_10_1158_1078_0432_CCR_05_1136 crossref_primary_10_18632_oncotarget_19088 crossref_primary_10_1016_j_tvjl_2015_02_020 crossref_primary_10_1111_cas_12819 crossref_primary_10_1198_sbr_2009_0040 crossref_primary_10_1007_s00262_004_0581_1 crossref_primary_10_1007_s10637_016_0335_x crossref_primary_10_1517_14712590903431022 crossref_primary_10_1007_s12094_006_0063_3 crossref_primary_10_1097_00002371_200403000_00006 crossref_primary_10_1177_1534735416651492 crossref_primary_10_1200_JCO_2005_01_149 crossref_primary_10_1038_sj_bjc_6602604 crossref_primary_10_1111_j_1541_0420_2008_01007_x crossref_primary_10_1158_1078_0432_CCR_05_2061 crossref_primary_10_1007_s11684_007_0003_9 crossref_primary_10_1007_s10585_021_10091_1 crossref_primary_10_1111_j_1541_0420_2008_01004_4_x crossref_primary_10_1200_JCO_2004_11_120 crossref_primary_10_1093_annonc_mdr396 crossref_primary_10_1177_0272989X07303826 crossref_primary_10_1073_pnas_242600099 crossref_primary_10_1093_annonc_mdt375 crossref_primary_10_1634_theoncologist_7_3_217 crossref_primary_10_1111_bju_15227 crossref_primary_10_1111_j_0105_2896_2004_00137_x crossref_primary_10_1111_j_0105_2896_2004_00139_x crossref_primary_10_1016_S1359_6446_02_02351_6 crossref_primary_10_1200_JCO_2005_02_0933 crossref_primary_10_1200_JCO_2006_10_3465 crossref_primary_10_1007_s00262_004_0607_8 crossref_primary_10_1016_j_jaut_2016_03_008 crossref_primary_10_1080_21645515_2017_1316910 crossref_primary_10_1097_00002371_200407000_00006 crossref_primary_10_1016_S0092_8674_01_00448_2 crossref_primary_10_1002_pst_251 crossref_primary_10_1016_j_ygyno_2012_12_004 crossref_primary_10_1080_10543400902800478 crossref_primary_10_1111_j_1365_2567_2005_02126_x crossref_primary_10_1002_pst_450 crossref_primary_10_1080_07357900600705516 crossref_primary_10_1186_1479_5876_5_67 crossref_primary_10_1208_ps050427 crossref_primary_10_3310_eme03030 crossref_primary_10_1007_s00262_004_0567_z crossref_primary_10_1517_13543784_16_8_1137 crossref_primary_10_1002_sim_8021 crossref_primary_10_1038_sj_onc_1205074 crossref_primary_10_1002_ijc_22097 crossref_primary_10_1007_s00262_011_1100_9 crossref_primary_10_1016_j_ejphar_2009_09_069 crossref_primary_10_1177_1740774518770661 crossref_primary_10_1245_ASO_2004_03_022 crossref_primary_10_1016_j_cct_2006_05_003 crossref_primary_10_1034_j_1600_0463_2003_11107813_x crossref_primary_10_1016_j_cct_2006_05_009 crossref_primary_10_1017_S0317167100005503 crossref_primary_10_1198_sbr_2009_0027 crossref_primary_10_1038_s41571_022_00643_z crossref_primary_10_1016_j_hoc_2007_08_011 crossref_primary_10_1016_j_cct_2015_01_016 crossref_primary_10_1038_nrc1359 crossref_primary_10_1097_COC_0b013e318172dccd crossref_primary_10_1159_000083223 crossref_primary_10_1097_00002371_200307000_00009 crossref_primary_10_1016_S0749_2081_03_00048_2 crossref_primary_10_1002_pros_21261 crossref_primary_10_1158_1078_0432_CCR_08_3205 crossref_primary_10_1200_JCO_2008_17_3138 crossref_primary_10_1158_1078_0432_CCR_08_2031 crossref_primary_10_1002_ijc_10777 crossref_primary_10_1093_biostatistics_kxx016 crossref_primary_10_1158_1078_0432_CCR_14_2565 crossref_primary_10_1016_j_lungcan_2009_10_001 crossref_primary_10_1038_bjc_2011_103 crossref_primary_10_1038_nrc820 crossref_primary_10_18632_oncotarget_10883 crossref_primary_10_1186_1479_5876_4_36 crossref_primary_10_1016_S1470_2045_03_01078_7 crossref_primary_10_1200_JCO_2008_18_6015 crossref_primary_10_1016_j_transproceed_2010_07_028 |
Cites_doi | 10.1002/sim.4780141308 10.2307/2533868 10.1016/0021-9681(80)90017-X 10.1038/nm0398-321 10.1016/0197-2456(94)90004-3 10.2307/2533060 10.1016/0197-2456(89)90015-9 10.2307/2533949 10.2307/2530863 10.1002/sim.4780140404 10.1016/0895-4356(88)90025-X 10.1038/13928 |
ContentType | Journal Article |
Copyright | 2001 INIST-CNRS |
Copyright_xml | – notice: 2001 INIST-CNRS |
DBID | IQODW CGR CUY CVF ECM EIF NPM AAYXX CITATION |
DOI | 10.1200/jco.2001.19.6.1848 |
DatabaseName | Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef |
DatabaseTitleList | CrossRef MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine Pharmacy, Therapeutics, & Pharmacology |
EISSN | 1527-7755 |
EndPage | 1854 |
ExternalDocumentID | 10_1200_JCO_2001_19_6_1848 11251017 938024 jco19_6_1848 |
Genre | Journal Article |
GroupedDBID | - 08R 0R 2WC 34G 39C 3O- 4.4 53G 55 5GY 5RE 8F7 8WZ A6W AARDX AAWTL AAYEP ABFLS ABOCM ACGFS ADBIT AENEX AFFNX ALMA_UNASSIGNED_HOLDINGS ASPBG AVWKF AWKKM AZFZN CS3 DIK EBS EJD EX3 F5P FD8 FH7 GJ H13 HZ IH2 KQ8 L7B N9A O9- OK1 OVD OWW P2P RHI RUC SJN SV3 TWZ UDS VH1 WH7 WOQ WOW X7M YCJ ZA5 ZGI --- .55 .GJ 08G 08P 0R~ 18M 29K 5VS AAKAS AAQQT AAUGY AAYOK ACGFO ADBBV ADZCM AEGXH AI. AIAGR BAWUL C45 D-I F9R FBNNL FEDTE GX1 HZ~ IPNFZ IQODW J5H K-O LSO MJL N4W NTWIH QTD R1G RIG RLZ TEORI TR2 UHU VVN YFH YQY ABJNI CGR CUY CVF ECM EIF NPM AAYXX CITATION |
ID | FETCH-LOGICAL-c424t-430c77a699f2cecdd355dc21bde688cbe5809db59297346ca232540f8436dae43 |
ISSN | 0732-183X |
IngestDate | Fri Aug 23 02:51:46 EDT 2024 Sat Sep 28 07:36:08 EDT 2024 Sun Oct 22 16:09:35 EDT 2023 Tue Jan 05 20:17:16 EST 2021 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 6 |
Keywords | Antineoplastic agent Human Randomization Treatment Immunotherapy Clinical trial Vaccine Review Malignant tumor Comparative study |
Language | English |
License | CC BY 4.0 |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c424t-430c77a699f2cecdd355dc21bde688cbe5809db59297346ca232540f8436dae43 |
PMID | 11251017 |
PageCount | 7 |
ParticipantIDs | crossref_primary_10_1200_JCO_2001_19_6_1848 pubmed_primary_11251017 pascalfrancis_primary_938024 highwire_smallpub2_jco19_6_1848 |
ProviderPackageCode | RHI |
PublicationCentury | 2000 |
PublicationDate | 2001-03-15 |
PublicationDateYYYYMMDD | 2001-03-15 |
PublicationDate_xml | – month: 03 year: 2001 text: 2001-03-15 day: 15 |
PublicationDecade | 2000 |
PublicationPlace | Baltimore, MD |
PublicationPlace_xml | – name: Baltimore, MD – name: United States |
PublicationTitle | Journal of clinical oncology |
PublicationTitleAlternate | J Clin Oncol |
PublicationYear | 2001 |
Publisher | American Society of Clinical Oncology Lippincott Williams & Wilkins |
Publisher_xml | – name: American Society of Clinical Oncology – name: Lippincott Williams & Wilkins |
References | R3-086625 R10-086625 R7-086625 R5-086625 R12-086625 R1-086625 R2-086625 R4-086625 R6-086625 R8-086625 R11-086625 R13-086625 R9-086625 R14-086625 R15-086625 |
References_xml | – ident: R8-086625 doi: 10.1002/sim.4780141308 – ident: R10-086625 doi: 10.2307/2533868 – ident: R13-086625 doi: 10.1016/0021-9681(80)90017-X – ident: R3-086625 doi: 10.1038/nm0398-321 – ident: R11-086625 doi: 10.1016/0197-2456(94)90004-3 – ident: R9-086625 doi: 10.2307/2533060 – ident: R5-086625 doi: 10.1016/0197-2456(89)90015-9 – ident: R15-086625 doi: 10.2307/2533949 – ident: R7-086625 doi: 10.2307/2530863 – ident: R2-086625 – ident: R6-086625 – ident: R12-086625 doi: 10.1002/sim.4780140404 – ident: R14-086625 doi: 10.1016/0895-4356(88)90025-X – ident: R4-086625 doi: 10.1038/13928 – ident: R1-086625 |
SSID | ssj0014835 |
Score | 2.0408385 |
Snippet | There are major differences between therapeutic tumor vaccines and chemotherapeutic agents that have important implications for the design of early clinical... |
SourceID | crossref pubmed pascalfrancis highwire |
SourceType | Aggregation Database Index Database Publisher |
StartPage | 1848 |
SubjectTerms | Adjuvants, Immunologic - therapeutic use Antineoplastic agents Antineoplastic Agents - therapeutic use Biological and medical sciences Cancer Vaccines - therapeutic use Cohort Studies Endpoint Determination Humans Immunocompromised Host Immunotherapy Medical sciences Neoplasms - drug therapy Neoplasms - virology Pharmacology. Drug treatments Randomized Controlled Trials as Topic Research Design Treatment Outcome |
Title | Clinical Trial Designs for the Early Clinical Development of Therapeutic Cancer Vaccines |
URI | http://jco.ascopubs.org/content/19/6/1848.abstract https://www.ncbi.nlm.nih.gov/pubmed/11251017 |
Volume | 19 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bT9swFLYYk9Bepg3Y6GDMD4gXSJe4zsWPqAKhIW6iSH2LHNsRoNIiWpDg1-_4lksBaeMlipLIjvx9PT0--c45CG0xAm4nF2VQUJYGVFEScCFUIEUW85KVYWziHccnyeEl_TOMh7WU12SXzIqueH41r-Q9qMI1wFVnyf4HstWgcAHOAV84AsJw_CeM-z6t0fbekEaNMa2Ug8oUL65yH2WtD3LKAJ95paVfQt3vPMICahn8Gx5rNdJkLFrR-AsA3O7lm-2J1XUlHrtoBF11RMVr9uvA9whe_krZ1s57rVCE0WLZZExnsdIeCcBGDFvmlTVo1LSVsLfMXjXixPSnvhEmNzPqRqybdOcfBiDubg2skXbRQpsAOlc629_6gD4SsENa8Xd0Xn9kopntv-rf2uVUwaS_X06uq8u64doujC8rrVW1fAoglLYjytw-xfgrgy_os4MN71nWfEULaryMlo6dlGIZbZ_ZouVPu3hQM2G6i7fxWV3O_GkFDT3LsGEZdizDwDIMHMKGZdhzAzdYhiclbrAMW5Zhz7JVdHmwP-gfBq4fRyAoobOA9kKRpjxhrCRCCSnBV5WCRIVUSZaJQsVZyGQRM90PjSaCg7cOG4Iyo71EckV739DieDJWawhLsP08FFHMo4ImYBhYqnQ2WSrhX6DgZQft-CXO72zZlVxvV4n-9to_1c1TozxieZJrbDrol0chn97y0QgWnuSAYeOJjRY41aDACvBSO-i7xaqezGH948076-hT_RvYQIuz-wf1ExzUWbFpaPYX2m2OEA |
link.rule.ids | 315,783,787,27938,27939 |
linkProvider | Colorado Alliance of Research Libraries |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Clinical+trial+designs+for+the+early+clinical+development+of+therapeutic+cancer+vaccines&rft.jtitle=Journal+of+clinical+oncology&rft.au=Simon%2C+R+M&rft.au=Steinberg%2C+S+M&rft.au=Hamilton%2C+M&rft.au=Hildesheim%2C+A&rft.date=2001-03-15&rft.issn=0732-183X&rft.volume=19&rft.issue=6&rft.spage=1848&rft_id=info:doi/10.1200%2Fjco.2001.19.6.1848&rft_id=info%3Apmid%2F11251017&rft.externalDocID=11251017 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0732-183X&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0732-183X&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0732-183X&client=summon |